National Cancer Institute
Fellowship
University of Chicago Medicine
Fellowship
University of California
San Francisco
Residency
Harvard Medical School
MD
NRG-BR002: A Randomized Phase II/III Trial of Metastasis-Directed Ablation With First-Line Systemic Therapy for Oligometastatic Breast Cancer.
NRG-BR002: A Randomized Phase II/III Trial of Metastasis-Directed Ablation With First-Line Systemic Therapy for Oligometastatic Breast Cancer. J Clin Oncol. 2026 Oct 07; JCO2600201.
PMID: 42842849
Impact of Time to Surgery Post Neoadjuvant Chemotherapy on Breast Cancer Outcomes: A Retrospective Study of Patients Enrolled in the I-SPY 2 Clinical Trial.
Impact of Time to Surgery Post Neoadjuvant Chemotherapy on Breast Cancer Outcomes: A Retrospective Study of Patients Enrolled in the I-SPY 2 Clinical Trial. Ann Surg Oncol. 2025 Oct; 32(11):8113-8126.
PMID: 40849380
Disparities in the Surgical Management of the Axilla by Self-Identified Race in the Multicenter Neoadjuvant I-SPY2 Trial.
Disparities in the Surgical Management of the Axilla by Self-Identified Race in the Multicenter Neoadjuvant I-SPY2 Trial. Ann Surg Oncol. 2025 Oct; 32(11):8211-8219.
PMID: 40699532
Longitudinal Changes in Stress and Isolation Among Multi-Ethnic Breast Cancer Survivors Throughout COVID-19.
Longitudinal Changes in Stress and Isolation Among Multi-Ethnic Breast Cancer Survivors Throughout COVID-19. Stress Health. 2025 Jun; 41(3):e70063.
PMID: 40530703
Oncologic Outcomes with De-Escalation of Axillary Surgery After Neoadjuvant Chemotherapy for Breast Cancer: Results from > 1500 Patients on the I-SPY2 Clinical Trial.
Oncologic Outcomes with De-Escalation of Axillary Surgery After Neoadjuvant Chemotherapy for Breast Cancer: Results from > 1500 Patients on the I-SPY2 Clinical Trial. Ann Surg Oncol. 2025 May; 32(5):3278-3291.
PMID: 39946078
ASO Visual Abstract: Internal Mammary Lymphadenopathy Does Not Impact Oncologic Outcomes in Patients Treated with Neoadjuvant Chemotherapy-Results from the I-SPY2 Clinical Trial.
ASO Visual Abstract: Internal Mammary Lymphadenopathy Does Not Impact Oncologic Outcomes in Patients Treated with Neoadjuvant Chemotherapy-Results from the I-SPY2 Clinical Trial. Ann Surg Oncol. 2024 Aug 03.
PMID: 39097555
Internal Mammary Lymphadenopathy Does Not Impact Oncologic Outcomes in Patients Treated with Neoadjuvant Chemotherapy: Results from the I-SPY2 Clinical Trial.
Internal Mammary Lymphadenopathy Does Not Impact Oncologic Outcomes in Patients Treated with Neoadjuvant Chemotherapy: Results from the I-SPY2 Clinical Trial. Ann Surg Oncol. 2024 Oct; 31(11):7420-7428.
PMID: 38980586
Validation of the RSClin risk calculator in the National Cancer Data Base.
Validation of the RSClin risk calculator in the National Cancer Data Base. Cancer. 2024 04 15; 130(8):1210-1220.
PMID: 38146744
Stress, Isolation, and Sleep Quality among Breast Cancer Survivors throughout the COVID-19 Pandemic: A Longitudinal Study in a Multi-Ethnic Cohort.
Stress, Isolation, and Sleep Quality among Breast Cancer Survivors throughout the COVID-19 Pandemic: A Longitudinal Study in a Multi-Ethnic Cohort. Res Sq. 2023 Aug 10.
PMID: 37609132
The impact of race and age on response to neoadjuvant therapy and long-term outcomes in Black and White women with early-stage breast cancer.
The impact of race and age on response to neoadjuvant therapy and long-term outcomes in Black and White women with early-stage breast cancer. Breast Cancer Res Treat. 2023 Jul; 200(1):75-83.
PMID: 37120458